Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 10 IN PLASTIC CONTAINER.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% w/ Electrolytes in Dextrose 25% is a parenteral nutrition formulation providing amino acids for protein synthesis and dextrose as a carbohydrate calorie source. The amino acids serve as substrates for protein synthesis, while dextrose provides glucose for cellular energy metabolism via glycolysis and the citric acid cycle. Electrolytes are included to maintain acid-base and fluid balance, and to support enzymatic functions and membrane potentials.
Travasol 10% (amino acids injection) provides essential and non-essential amino acids for protein synthesis and nitrogen equilibrium in patients unable to obtain adequate nutrition orally or enterally. Amino acids are building blocks for proteins; they also serve as substrates for gluconeogenesis and other metabolic pathways.
Intravenous infusion. Adult dose: 500 mL to 1000 mL per 24 hours, adjusted to meet protein and calorie requirements. Typical infusion rate: 1.5-2.0 mL/kg/hour, not exceeding 3.0 mL/kg/hour.
Intravenous infusion: 500 mL to 2 L per day, administered at a rate not exceeding 4 mL/kg/h. Typical adult dose is 1-2 g protein/kg/day (equivalent to 10-20 mL/kg/day of 10% solution). Rate and volume are adjusted based on patient's metabolic needs and clinical status.
None Documented
None Documented
Not applicable as a single entity; amino acids have rapid turnover (minutes to hours) with no terminal half-life. Dextrose has a half-life of 15-20 minutes under steady-state conditions.
Not applicable as a single entity; constituent amino acids have half-lives varying from minutes to hours (e.g., 10-30 min for most). Clinical context: continuous infusion maintains steady state.
Amino acids are metabolized to urea (liver) and CO2; nitrogen is excreted renally as urea (80-90%), with minimal (<5%) biliary/fecal. Dextrose is metabolized to CO2 (exhaled) and water. Electrolytes are excreted renally proportional to intake and homeostasis.
Renal excretion of infused amino acids and their metabolites; excess nitrogen excreted as urea in urine. ~90-95% of infused amino acids are utilized or excreted renally. Fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution